Lowering LDL fast after a heart attack gets more patients to goal, but one year showed no fewer events

Table of Contents

1.0 Summary

Two trials presented at ESC Congress 2026 looked at how quickly to intensify cholesterol treatment after a heart attack. AMUNDSEN gave 2,161 patients having a heart attack either the injectable PCSK9 inhibitor evolocumab, starting before their stent procedure, on top of standard treatment, or standard treatment alone. At one year 82% of the evolocumab group had an LDL cholesterol below 55 mg/dL with at least a 50% reduction, against 40% on standard care, but death or unplanned cardiovascular hospitalization occurred in about 15% of both groups. BRIDGE, a smaller study of 329 patients in 10 Japanese hospitals, found that a written treatment protocol got more patients to LDL goals at six months than usual care. BRIDGE measured goal attainment only, AMUNDSEN’s one-year follow-up was short, and this summary relies on conference news reports rather than the full journal articles.

2.0 Key Points

  1. In AMUNDSEN, 2,161 patients with acute myocardial infarction were randomized to evolocumab 140 mg every two weeks for one year, with the first dose before PCI, plus standard care, or to standard care alone.
  2. An LDL cholesterol below 55 mg/dL with at least a 50% reduction at 12 months was reached by 82% with evolocumab and 40% with standard care; median LDL cholesterol at six weeks was 16 vs 56 mg/dL.
  3. All-cause death or unplanned cardiovascular hospitalization at 12 months occurred in about 15% of patients in both groups, and 1 in 5 evolocumab patients still missed the LDL target at one year.
  4. In BRIDGE, a protocol-based strategy after emergency PCI raised the share of patients with LDL cholesterol below 70 mg/dL at six months to 86.4% from 73.7% (p = 0.005), and below 55 mg/dL to 60.8% from 34.5% (p < 0.001).
  5. BRIDGE’s hospital-level analysis was not statistically significant (p = 0.08) and the trial measured only LDL goals, while AMUNDSEN’s 12-month follow-up is likely too short to show the event benefit of lower LDL cholesterol.

3.0 Evidence base

AMUNDSEN tested whether starting the most potent available treatment right away makes a difference. Researchers at 46 sites in six countries enrolled 2,161 patients having a heart attack and about to undergo percutaneous coronary intervention (PCI), the procedure that opens a blocked coronary artery and places a stent. The mean age was 67 and 79% were men. Nearly 60% had a STEMI, the type of heart attack in which an artery is fully blocked, and 40% had an NSTEMI [1]. Half received evolocumab, an injectable PCSK9 inhibitor, at 140 mg every two weeks for a year, with the first injection given before PCI, on top of standard care. The other half received standard care alone: high-intensity oral cholesterol-lowering drugs, with a PCSK9 inhibitor allowed when guidelines called for one [1]. The trial was published in JAMA [3].

The primary outcome was an LDL cholesterol below 55 mg/dL, the guideline-recommended target, together with at least a 50% fall from baseline at 12 months. It was reached by 82% of the evolocumab group and 40% of the standard care group. At six weeks, median LDL cholesterol was 16 mg/dL with evolocumab and 56 mg/dL with standard care [1].

That large gap in LDL did not produce a difference in events within the year. The main clinical endpoint, death from any cause or unplanned hospitalization for a cardiovascular reason, occurred in about 15% of patients in each group [1]. Even with evolocumab started immediately, about one patient in five had not reached the target at one year [1].

BRIDGE asked a more everyday question: whether a written protocol does better than leaving intensification to each clinician. Ten hospitals in Japan were randomly assigned, as whole sites, to protocol-based or standard lipid management between November 2024 and July 2025 [2]. For patients hospitalized for emergency PCI, the protocol started high-intensity statins, ezetimibe and PCSK9 inhibitors earlier, following a prespecified algorithm based on each patient’s existing treatment and LDL level, with LDL checked at four weeks. The 329 patients analyzed had a mean age of 69, 18% were women, and their median LDL cholesterol was 110 mg/dL [2].

At six months, 86.4% of patients in the protocol group had an LDL cholesterol below 70 mg/dL, compared with 73.7% under standard care, a difference of 12.6 percentage points (p = 0.005). For below 55 mg/dL the figures were 60.8% and 34.5%, a difference of 26.3 points (p < 0.001). The protocol group used more high-intensity statins, ezetimibe and PCSK9 inhibitors [2].

4.0 Where it fits in practice

Neither trial changes the LDL goal after a heart attack. Both are about how to reach it. BRIDGE suggests that a written protocol, using drugs that are already widely available, gets more patients to goal within six months than case-by-case decisions [2]. Its lead author described a structured, protocol-based pathway as a practical and scalable way to make guideline-directed lipid management more consistent after an acute coronary syndrome [2].

AMUNDSEN shows that starting evolocumab before PCI brings LDL cholesterol down quickly and keeps more patients at target for a year, but it gives no reason to expect fewer events in that first year [1]. The investigators read this as a sign that evolocumab may not have meaningful early effects beyond lowering LDL, and that the benefit of LDL lowering may take more time to appear [1]. An accompanying editorial described the benefit of LDL lowering after a heart attack as a marathon rather than a sprint: a rapid reduction at seven days will take years to translate into meaningful clinical benefit [1].

This site’s steps for intensifying treatment after an acute coronary event are in /clinical/05-treatment-pathways.html, and the timing of repeat lipid testing is in /clinical/12-follow-up-protocol.html.

5.0 Open questions

AMUNDSEN followed patients for 12 months, which is likely too short to see differences in heart attacks and deaths from lowering LDL cholesterol [1]. Patients in the standard care group could also receive a PCSK9 inhibitor when guidelines indicated one, which narrows the contrast between the groups [1]. These data cannot say whether the early LDL advantage becomes fewer events over several years.

BRIDGE was small and measured LDL goal attainment, not heart attacks or deaths. Because hospitals rather than individual patients were randomized, the hospital-level comparison matters, and there the difference in reaching below 70 mg/dL was 12.8 percentage points but not statistically significant (p = 0.08) [2]. It was run at 10 centers in Japan.

The AMUNDSEN editorialists also argued that the larger gain may come from starting LDL lowering earlier, even modestly, in people who do not yet have clinically manifest disease [1]. Neither trial tested that.

Both accounts come from American College of Cardiology news coverage of the ESC Congress 2026 presentations, not the full JAMA and JACC papers [1, 2, 3].

This summary is provided for clinical decision support only and does not replace individualized clinical judgment. Findings are summarized from the cited primary sources; consult those sources before changing practice.

Version History

Version Date Description
1.0.0 2026-09-14 Initial release

References

  1. AMUNDSEN: Evolocumab vs. Standard Care in Lowering LDL-C Before PCI For Acute MI. https://www.acc.org/Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-amundsen-esc-2026.
  2. BRIDGE, ALPACA Studies Examine Protocol-Based LLT, Novel Lepodisiran in Lipid Management. https://www.acc.org/Latest-in-Cardiology/Articles/2026/08/29/08/48/mon-jacc-lipids-esc-2026.
  3. Montalescot G et al. LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial. JAMA. 2026-08-29. doi:10.1001/jama.2026.17302. Available at: https://doi.org/10.1001/jama.2026.17302

© 2026 The Sandusky Dyslipidemia Model. For clinical decision support only. Not a substitute for clinical judgment.